Request for Proposals and Ad-hoc Requests supports academic and industry investigators in Friedreich’s ataxia research to advance therapies, fill research gaps, and develop research tools.
Funder: Friedreich's Ataxia Research Alliance
Due Dates: May 1, 2027 (LOI) | July 1, 2027 (Application) | Off-cycle (Ad-hoc requests)
Funding Amounts: Up to $250,000 per year for up to two years; direct costs only
Summary: Supports Friedreich’s ataxia research through targeted requests for proposals and high-value, off-cycle research requests.
Key Information: Industry applicants must demonstrate participation in the FA research community and advance therapeutic candidates for FA.
The Friedreich’s Ataxia Research Alliance (FARA) supports research spanning basic science, drug development, and clinical research in Friedreich’s ataxia (FA). Through this program, FARA announces targeted requests for proposals (RFPs) and considers high-value ad-hoc proposals outside its regular funding cycle. Its broader goals include advancing therapeutic development, filling research gaps, developing research tools, and promoting collaboration among academic and industry investigators.
The blood-based biomarker initiative seeks biologically meaningful monitoring biomarkers downstream of frataxin that can track disease progression and therapeutic response. It welcomes targeted and exploratory discovery approaches with well-defined objectives and a clear path from discovery to validation. Applicants are strongly encouraged to use existing plasma or serum samples from previous interventional or natural-history studies.